Stocks in play: StageZero Life Sciences
Today announced its first quarter financial results for the three months ended March 31, 2023. For the quarter, the Company generated revenue of $0.779 million, compared to revenue of $0.676 million for the three months ended December 31, 2022. Net loss was $1.8 million, or $0.02 loss per fully diluted common share in Q1 2023 as compared to a $9.5 million net loss, or $0.09 loss per fully diluted common share in Q4 2022. StageZero Life Sciences shares T.SZLS are trading down $0.01 at $0.06.
Read:
Global Lithium Supply Under Pressure as South American Nations Discuss "Lithium OPEC"
International Lithium Buyers Looking to South America to Fill Supply Gaps
Race to Secure Critical EV Battery Metals Ahead of Chinese Dominance Fully Underway
Help is on the Way as Rising Alzheimer’s Cases Highlight Urgency for New Treatments
FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023